New ARV not for women wanting to fall pregnant
South Africa stopped its planned switch to dolutegravir in June after a study in Botswana found that four women out of 596 pregnant women on the drug had given birth to babies with neural tube defects.
But Dr Rebecca Zash, from the Botswana-Harvard AIDS Institute Partnership, told the International AIDS Conference that it seemed that only babies born to women who had been taking dolutegravir at conception were at risk.
“Dolutegravir was just as safe as efavirenz [the ARV it replaced] for women who started on dolutegravir during pregnancy,” said Zash, but said that more information about the drug was needed.
“The study was small. We have since had another 170 births with no defects, but we need more data,” said Zash.
Neural tube defects happen in the first 28 days after conception.
Benefits of dolutegravir
Dolutegravir is easily tolerated, suppresses the virus faster than many other ARVs and the virus does not develop resistance to it fast.
Botwana switched to dolutegravir in June 2016, and South Africa was due to follow suit this June. A modeling study of a dolutegravir-based treatment regimen predicted that it could prevent over 25,000 deaths among women and 5,000 child infections compared to efavirenz-based ART over five years in South Africa.
Civil society delegates staged a protest at the conference demanding that women be given the right to choose between dolutegravir and efavirenz.
However, scientists said that women on dolutegravir must be on contraception until safety concerns are addressed.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
New ARV not for women wanting to fall pregnant
by kerrycullinan, Health-e News
July 26, 2018